NEW YORK, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in women's cancer, such as breast and gynecologic cancers, today announced acceptance of a late-breaking poster presentation at the 2014 San Antonio Breast Cancer Symposium taking place December 9-13, 2014 in San Antonio, Texas.
The poster titled, "Provista-001: a multi-center prospective study of protein signature used in the differentiation of benign breast lesions from invasive breast cancer in women under the age of 50 with a BI-RADS 3 or 4," will be presented in the Detection and Diagnosis Poster Session.
The American College of Radiology (ACR) utilizes a standard reporting system to describe mammogram findings and results called the Breast Imaging Reporting and Data System (BI-RADS®). This system defines assessment categories that are predictive of the likelihood of malignancy and the results are sorted into classifications numbered 0 through 6. BI-RADS® 3 and 4 lesions represent a key decision point for radiologists as to biopsy or reassess via imaging in six months.
The poster will highlight data from the Company's 001 randomized, blinded prospective trial consisting of 351 women under the age of 50 whose suspicious mammograms were scored as either BI-RADS® 3 or 4. The study enrolled volunteers at 10 sites across the U.S. These women were assessed with Provista's proprietary diagnostic test that is used in combination with standard imaging. The results will demonstrate the ability of the combinatorial profile of Serum Protein Biomarkers (SPB), select patient data and Tumor Associated Autoantibodies (TAA) to help differentiate benign from cancerous lesions in a prospective setting. The ultimate objective is a more precise identification of deadly breast cancers in women.
Provista Diagnostics is currently conducting multiple trials to establish the combined role of SPBs and TAAs to differentiate benign from invasive breast cancers in woman 25 to 75 years old.
"We are very excited to be accepted to present our late-breaking data at the 2014 San Antonio Breast Symposium, as it is one of the premier clinical and scientific meetings focused on breast cancer diagnosis and treatment," said David Reese, Ph.D., President and CEO of Provista.
According to the American Cancer Society, nearly 233,000 women will be diagnosed with breast cancer in the U.S. in 2014. Approximately 40,000 deaths occur from breast cancer each year. While biomarkers are often used to augment detection of various cancers, definitive biomarkers for breast cancer have remained elusive.
About Provista Diagnostics, Inc.
Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in women's cancer, such as breast and gynecologic cancers. Additionally, Provista offers companion diagnostic services to the life sciences industry. Provista Diagnostics' state-of-the-art, high complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and certified by the Centers for Medicare and Medicaid Services (CMS) to be compliant with the Clinical Laboratory Improvement Amendments (CLIA).
Additional information about Provista Diagnostics is available at Provistadx.com.
Information about Provista Diagnostics' clinical trials is available at www.clinicaltrials.gov.
About the San Antonio Breast Cancer Symposium
For thirty-seven years, the Symposium's mission has been to provide state-of-the-art information on breast cancer research. From a one-day regional conference, the Symposium has grown to a five-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.
The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.
In 2007, the Cancer Therapy & Research Center (CTRC) at UT Health Science Center San Antonio and the American Association for Cancer Research (AACR) announced a collaboration for the future of the San Antonio Breast Cancer Symposium. The Symposium has been renamed the CTRC-AACR San Antonio Breast Cancer Symposium. Complementing the clinical strengths of the highly regarded annual San Antonio Breast Cancer Symposium, the AACR's scientific prestige in basic, translational and clinical cancer research will create a unique and comprehensive scientific meeting that will advance breast cancer research for the benefit of patients.
In 2005, Baylor College of Medicine became a joint sponsor of the symposium and will remain in the CTRC-AACR collaboration.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
CONTACT: David R. Holmes Provista Diagnostics, Inc. HolmesD@ProvistaDx.com (212) 202-3170Source:Provista Diagnostics